Burkitt's lymphoma-- what is new?
Abinya
Othieno N A
ON
D000349:Africa / Q000453:epidemiology; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000473:pathology; D002051:Burkitt Lymphoma / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology / Q000473:pathology; D002648:Child; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D020031:Epstein-Barr Virus Infections / Q000150:complications; D005260:Female; D006801:Humans; D008288:Malaria / Q000150:complications; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D000069283:Rituximab; D014750:Vincristine / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD; D000069283:Rituximab; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D008727:Methotrexate